Navigation Links
Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
Date:9/1/2008

6]** 1.8 [0.4-5.1]

60mg 15.2 [10.0-21.8]** 2.2 [0.6-5.4]

90mg 10.6 [6.2-16.6]** 2.3 [0.6-5.7]

#95% confidence interval, * p=0.005, **p<0.001, ***Major+Clinically

Relevant

About DU-176b

DU-176b is an oral anticoagulant that directly inhibits Factor Xa, a clotting factor in the blood. Daiichi Sankyo is developing DU-176b as a potential new treatment for the prevention of both arterial and venous thromboembolism.

About Daiichi Sankyo

A global pharmaceutical innovator, Daiichi Sankyo Co., Ltd., headed by President Takashi Shoda was established in 2005 through the merger of two leading Japanese pharmaceutical companies, Daiichi Pharmaceutical Co., Ltd. and Sankyo Co., Ltd. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development is cardiometabolic diseases, including therapies for thrombosis, dyslipidemia, hypertension, diabetes, and acute coronary syndromes. Equally important to the company is the discovery of new medicines in the areas of infectious diseases, cancer, bone and joint diseases, and immune disorders. For more information, visit http://www.daiichisankyo.com.


'/>"/>
SOURCE Daiichi Sankyo
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
3. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
4. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 Research and Markets ... "New EU Pharmacovigilance Legislation (London, UK - November ... The 15 new EU modules concerning Pharmacovigilance are ... is conducted in Europe . The ... modules and their requirements, examine how they overlap and ...
(Date:9/2/2015)... Sep. 02, 2015 ... the addition of Jain PharmaBiotech,s new report ... to their offering. This report ... specialty, aimed at improving patient care by monitoring ... the dose of drugs for improving outcome. TDM ...
(Date:9/2/2015)... Calif. , Sept. 2, 2015  ArmaGen, ... developing revolutionary therapies to treat severe neurological disorders, ... dosed in its multi-center Phase 1/2a clinical trial ... I (MPS I). AGT-181 is ... treatment of MPS I. The most severe form ...
Breaking Medicine Technology:Global Therapeutic Drug Monitoring Technologies, Markets, and Companies Report 2015 - Updated 2015 Analysis with Forecasts to 2024 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4
... 23, 2007 - CytoGenix, Inc. (CYGX.OB),announced today that ... update on preclinical animal data for DNA vaccines ... 2007,DNA Vaccines conference to be held in Malaga, ... comments, "We have successfully conducted tests of,synDNA(TM) based ...
... VANCOUVER, British Columbia--(BUSINESS WIRE)--May 23, 2007 -,ProtoKinetix Inc. ... by ITTEC Stem, Inc. at the University of ... for stem cells demonstrate the vital importance of ... This is the,first series of tests using AAGP(TM) ...
Cached Medicine Technology:CytoGenix to Present at 2007 International DNA Vaccines Conference,in Spain 2ProtoKinetix's AAGP Dramatically Increases Recovery Rate of,Cryopreserved Stem Cells 2
(Date:9/2/2015)... ... 02, 2015 , ... The Hydration Room, Orange County’s first ... second location this week at 31542 S. Coast Hwy, Suite #4, Laguna Beach, ... for patients to relax while receiving safe and effective therapies. Also offering complimentary ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... companies, has completed a recapitalization with new investment partners Beecken Petty O’Keefe ... Group each offer extensive expertise and connections within the healthcare industry, which ...
(Date:9/2/2015)... ... September 02, 2015 , ... The ... two day international investment and business conference will be hosted at five star ... China. The full-weekend networking conference will feature leading EB-5 industry professionals and Chinese ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... patented products, announces Hand Free Pocket Cop, a safety invention that protects people ... US is worth $31 billion," says Scott Cooper, CEO and Creative Director of ...
(Date:9/2/2015)... ... September 02, 2015 , ... EDAC Systems, Inc., a leading ... and services to both government and commercial clients, today announced the release of ... IBM’s Datacap document capture platform. EDAC PurePAGE processes and enhances the images ...
Breaking Medicine News(10 mins):Health News:The Hydration Room Opens New Location In Laguna Beach, California 2Health News:The Hydration Room Opens New Location In Laguna Beach, California 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 4Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 3Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 4Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 3Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 4Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 5Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 6Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 7Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3
... for ambulatory care ... ... Cardiac Science,Corporation, (Nasdaq: CSCX ), a leading provider of ... of its HeartCentrix(R) ECG informatics software with Greenway,Medical Technology,s PrimeSuite(R) ...
... to US$5.5 million -, BELLEVILLE, ON, Dec. ... a research-based, technology-driven Canadian,biopharmaceutical company, today announced that ... its long-term convertible debt with Laurus Master,Funds., ... will now have a maximum,borrowing limit of US$5.5 ...
... Upon an ex parte motion,by the Service ... order (TRO) was issued late on Thursday, December ... County, Michigan,enjoining the Michigan Department of Community Health, ... Carlyle Group from taking certain actions related to,completing ...
... 20 Percent of Cost for New Hospital, SAN ... has reached its $50 million Capital Campaign,goal, the largest ... recent gift of $500,000 from the Stephen and Mary ... http://www.newscom.com/cgi-bin/prnh/20071220/DC10448 ), "It,s only fitting that ...
... For ... Breast Cancer Research., NEWPORT NEWS, Va., Dec. 20 ... Inc. of San Diego,California have settled their lawsuit over Dilon,s ... Dilon in the U.S.,District Court for the Southern District of ...
... gives DRAXIMAGE strong competitive position ... MONTREAL, Dec. 20 /PRNewswire-FirstCall/ - DRAXIMAGE, the,radiopharmaceutical ... (NASDAQ:,DRAX), has appointed GE Healthcare, an industry ... of DRAXIMAGE(R) Sestamibi in the United,States. DRAXIMAGE(R) ...
Cached Medicine News:Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies 2Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies 3Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies 4Health News:Bioniche Amends Terms of Convertible Debt with Laurus Master Funds 2Health News:Manor Care To Vigorously Contest TRO 2Health News:Sharp HealthCare Foundation Reaches $50 Million Goal 2Health News:Sharp HealthCare Foundation Reaches $50 Million Goal 3Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 2Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 3Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 4Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 5Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 6Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 7
... Accurately tests for Nystagmus when ... 10" high by 8" diameter. Light ... ball bearings for effortless spin mechanism. ... from patient. Includes both Adult and ...
Diagnose dry eye, assess the effectiveness of permanent punctal occlusion, collagen - dissolvable in 3-5 days, all are 2 mm long. Sterile...
Clear Base Stand Magnifiers are ideal for any visual task that requires high magnification....
Contour design eyelid implants....
Medicine Products: